Clinical Study
Systemic and Urinary Neutrophil Gelatinase-Associated Lipocalins Are Poor Predictors of Acute Kidney Injury in Unselected Critically Ill Patients
Table 1
Group characteristics.
| | | Patients who never developed AKI | Patients who developed AKI | Patients with AKI on admission | value | | |
() | () | () | |
| | Age (years) |
58.8 (16.1) | 67.1 (15.8) | 74.4 (9.4) | <0.05 | | Gender (male) (%) | 37 (64.9%) | 21 (67.7%) | 32 (61.5) | 0.84 | | Weight (kg) | 75.7 (14.7) | 81.6 (14.9) | 81.1 (19.7) | 0.17 | | Height (cm) | 176.0 (8.4) | 175.2 (8.5) | 171.2 (17.1) | 0.12 | | APACHE II score | 18.5 (9.4) | 19.3 (8.3) | 23 (11.5) | 0.06 | | SAPS II | 35.9 (12) | 42.8 (15) | 47.1 (14.8) | <0.05 | | RIFLE baseline sCr (mol/L) | 69.9 (18.7) | 77.9 (15.9) | 76.3 (19.8) | 0.16 | | sUrea (mmol/L) | 7.9 (5.9–11.2) | 11.7 (8.1–17.2) | 12.4 (8.1–22.4) | <0.05 | | sCr (mol/L) | 62 (50–78) | 86 (72–104) | 110 (73–177) | <0.05 | | sNGAL (ng/mL) | 269 (180–398) | 307 (187–460) | 343 (238–652) | <0.05 | | uNGAL (ng/mL) | 99 (41–301) | 149 (52–405) | 289 (92–602) | <0.05 | | uNGALcorr (mg/molCr) | 23 (9–64) | 40 (13–142) | 23 (8–101) | 0.05 | | Primary diagnosis () (%) | | | | | | CPB | 1 (1.7%) | 2 (6.4%) | — | 0.25 | | Cardiovascular failure | 1 (1.7%) | 4 (12.9%) | 4 (7.7%) | 0.11 | | Cerebrovascular event | 2 (3.5%) | 0 (0%) | 0 (0%) | — | | Hemorrhagic shock | 7 (12.3%) | 1 (3.2%) | 5 (9.6%) | 0.37 | | Multiple trauma | 3 (5.3%) | 2 (6.4%) | 1 (1.9%) | 0.55 | | Elective major surgery | 1 (1.8%) | 1 (3.2%) | 5 (9.6%) | 0.15 | | Respiratory failure | 22 (38.6%) | 10 (32.2%) | 14 (26.9%) | 0.43 | | Septic shock | 20 (35.1%) | 11 (35.5%) | 24 (46.2%) | 0.44 | | Admission category () (%) | | | | | | Medical | 27 (47.4%) | 14 (45.2%) | 21 (40.4%) | 0.76 | | Surgical | 30 (52.6%) | 17 (54.8%) | 31 (59.6%) | 0.76 | | Days from admission until AKI (median and range) | NA | 2 (1-2) | 0 | — | | Worst AKI score in ICU () (%) | | | | | | Risk | — | 25 (80%) | 22 (42%) | <0.05 | | Injury | — | 4 (12%) | 13 (25%) | 0.19 | | Failure | — | 2 (6%) | 17 (32%) | 0.006 | | CVVH | 1 (2%) | 3 (10%) | 8 (15%) | <0.05 | | LOS (days) | 5 (3–8) | 8 (5–18) | 6 (3–9) | 0.001 | | ICU mortality | 0 | 4 (13%) | 8 (15%) | <0.05 | | Hospital mortality | 4 (7.0%) | 5 (16.1%) | 15 (29%) | <0.05 |
|
|
